K. Eser, E. Sezer, V. Erçolak, A. Inal, A. Ata, Hakan Basir, M. Berkeşoğlu
The significance of relative dose intensity (RDI) in the treatment of various types of solid cancers has been studied. Nevertheless, RDI may not accurately reflect the treatment intensity of regorafenib, where the standard dose cannot be tolerated by most patients. We aimed to investigate the efficacy of the delivered dose intensity/body surface area (BSA) ratio at 2 months (2M-DBR) by comparing the relationship between 2M-DBR, RDI at 2 months, and the therapeutic response. Material and Methods: The thera- peutic response to regorafenib was studied in 53 patients retrospectively from 2015 to 2020. Computed tomography scans were performed at 8-12 weeks after the initiation of treatment. We also investigated the clinical factors associated with high 2M-DBR and BSA. Results: Pa- tients with high 2M-DBR achieved significantly better objective response rates than those with low 2M-DBR (p<0.064). Patients with high 2M-DBR experienced longer overall survival (p=0.445) and progression-free survival (p=0.524) than those with low 2M-DBR but the dif- ference was not statistically significant. Tolerance to 160 mg regorafenib was found to be better in patients with high BSA (22%) than in a patient with low BSA (0%) (p=0.011). Conclusion: BSA is crucial in determining the tolerance dose of regorafenib. 2M-DBR plays a key role in reflecting treatment intensity and is a useful tool for predicting the response to regorafenib in mCRC.
{"title":"Investigation of Regorafenib Efficacy in Patients with Metastatic Colorectal Carcinoma in Relation to the Delivered Dose Intensity/Body Surface Area","authors":"K. Eser, E. Sezer, V. Erçolak, A. Inal, A. Ata, Hakan Basir, M. Berkeşoğlu","doi":"10.37047/jos.2021-87466","DOIUrl":"https://doi.org/10.37047/jos.2021-87466","url":null,"abstract":"The significance of relative dose intensity (RDI) in the treatment of various types of solid cancers has been studied. Nevertheless, RDI may not accurately reflect the treatment intensity of regorafenib, where the standard dose cannot be tolerated by most patients. We aimed to investigate the efficacy of the delivered dose intensity/body surface area (BSA) ratio at 2 months (2M-DBR) by comparing the relationship between 2M-DBR, RDI at 2 months, and the therapeutic response. Material and Methods: The thera- peutic response to regorafenib was studied in 53 patients retrospectively from 2015 to 2020. Computed tomography scans were performed at 8-12 weeks after the initiation of treatment. We also investigated the clinical factors associated with high 2M-DBR and BSA. Results: Pa- tients with high 2M-DBR achieved significantly better objective response rates than those with low 2M-DBR (p<0.064). Patients with high 2M-DBR experienced longer overall survival (p=0.445) and progression-free survival (p=0.524) than those with low 2M-DBR but the dif- ference was not statistically significant. Tolerance to 160 mg regorafenib was found to be better in patients with high BSA (22%) than in a patient with low BSA (0%) (p=0.011). Conclusion: BSA is crucial in determining the tolerance dose of regorafenib. 2M-DBR plays a key role in reflecting treatment intensity and is a useful tool for predicting the response to regorafenib in mCRC.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Aykan, G. Yıldıran, R. Acar, Nazlıcan İğret, B. Yıldız, İ. Ertürk, N. Karadurmuş
study, patients with relapsed or refractory GCT and BM were evaluated. The characteristic clinical features of the patients, their systemic treatments, local treatments applied to BM, and follow-up periods were recorded. The primary endpoint was to assess survival after detection of synchronous and metachronous BM. The secondary endpoint was determined as overall survival (OS). Results: Twenty-five patients were included in this study with median age and interquartile range (IQR) of 30.24 and 7.92, respectively. Stage IIIC was detected at first diagnosis in 72% of the patients. The most commonly used local BM treatment was the combination of surgery and radiotherapy (60%). The objective response rate (complete response plus partial response) after local BM treatment was 60%. The median OS in the whole group was 24.75 (IQR: 25.97) months. The median OS (IQR) in the synchronous BM group was significantly different than that in the metachronous BM group [33.51 (18.13) vs. 9.97 (7.52), 95% confidence interval of 6.7 to 40.3 months, p=0.013]. There was no difference in the median OS between the groups [median (IQR)=36.39 (25.35) months vs. 23.70 (35.68) months, p=0.672]. Conclusion: The patients with GCTs presenting with BM during diagnosis were in a better condition than those who developed BM at relapse. However, no significant difference was found in OS. This may indicate shorter survival times for the patients who relapse, as the tumor is resistant to systemic therapy.
{"title":"Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience","authors":"M. Aykan, G. Yıldıran, R. Acar, Nazlıcan İğret, B. Yıldız, İ. Ertürk, N. Karadurmuş","doi":"10.37047/jos.2021-87403","DOIUrl":"https://doi.org/10.37047/jos.2021-87403","url":null,"abstract":"study, patients with relapsed or refractory GCT and BM were evaluated. The characteristic clinical features of the patients, their systemic treatments, local treatments applied to BM, and follow-up periods were recorded. The primary endpoint was to assess survival after detection of synchronous and metachronous BM. The secondary endpoint was determined as overall survival (OS). Results: Twenty-five patients were included in this study with median age and interquartile range (IQR) of 30.24 and 7.92, respectively. Stage IIIC was detected at first diagnosis in 72% of the patients. The most commonly used local BM treatment was the combination of surgery and radiotherapy (60%). The objective response rate (complete response plus partial response) after local BM treatment was 60%. The median OS in the whole group was 24.75 (IQR: 25.97) months. The median OS (IQR) in the synchronous BM group was significantly different than that in the metachronous BM group [33.51 (18.13) vs. 9.97 (7.52), 95% confidence interval of 6.7 to 40.3 months, p=0.013]. There was no difference in the median OS between the groups [median (IQR)=36.39 (25.35) months vs. 23.70 (35.68) months, p=0.672]. Conclusion: The patients with GCTs presenting with BM during diagnosis were in a better condition than those who developed BM at relapse. However, no significant difference was found in OS. This may indicate shorter survival times for the patients who relapse, as the tumor is resistant to systemic therapy.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
U. Disel, F. Köse, A. Bilici, M. Özgüroğlu, S. Saglam, M. Seker, S. Aksoy, I. Tek, N. Mandel, G. Demir, Ç. Arslan, M. Demiray, M. Öztürk, T. Salepçi, Y. Eralp, F. Selçukbiricik, Gokce Temizas, E. Fidan
ABS TRACT Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap- plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results : In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford- able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or laboratory tests.
{"title":"The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors","authors":"U. Disel, F. Köse, A. Bilici, M. Özgüroğlu, S. Saglam, M. Seker, S. Aksoy, I. Tek, N. Mandel, G. Demir, Ç. Arslan, M. Demiray, M. Öztürk, T. Salepçi, Y. Eralp, F. Selçukbiricik, Gokce Temizas, E. Fidan","doi":"10.37047/jos.2022-89310","DOIUrl":"https://doi.org/10.37047/jos.2022-89310","url":null,"abstract":"ABS TRACT Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap- plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results : In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford- able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or laboratory tests.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahsen Duygu Yetut, Semra Taş, F. Ekinci, Cumali Çelik, A. Erdoğan, A. Dirican
ABS TRACT Serpentine supravenous hyperpigmentation (SSH) is a rare complexity arising from antineoplastic therapy. Vinorelbine, a chemotherapeutic drug that is frequently used for the treatment of breast and lung cancer, contributes to the etiology of SSH. A 54 years old male patient was being treated for lung adenocarcinoma. An intravenous (IV) infusion of vinorelbine was administered in the distal dorsal vein of the left forearm. Erythematous hyperpigmentation at the infusion area was observed a week after the administration of the chemotherapeutic drug. The initial symptoms of SSH usually appear between 1 to 15 days post IV administration of a cytotoxic drug, and it spontaneously be- comes hyperpigmented within 1-3 weeks. However, these local reactions can be prevented by applying IV infusion for a short period (15-30 min) along with adequate venous irrigation (75-124 mL) instead of bolus administration. The termination of the drug can also be considered.
{"title":"Vinorelbine Induced Serpentine Supravenous Hyperpigmentation","authors":"Ahsen Duygu Yetut, Semra Taş, F. Ekinci, Cumali Çelik, A. Erdoğan, A. Dirican","doi":"10.37047/jos.2022-88125","DOIUrl":"https://doi.org/10.37047/jos.2022-88125","url":null,"abstract":"ABS TRACT Serpentine supravenous hyperpigmentation (SSH) is a rare complexity arising from antineoplastic therapy. Vinorelbine, a chemotherapeutic drug that is frequently used for the treatment of breast and lung cancer, contributes to the etiology of SSH. A 54 years old male patient was being treated for lung adenocarcinoma. An intravenous (IV) infusion of vinorelbine was administered in the distal dorsal vein of the left forearm. Erythematous hyperpigmentation at the infusion area was observed a week after the administration of the chemotherapeutic drug. The initial symptoms of SSH usually appear between 1 to 15 days post IV administration of a cytotoxic drug, and it spontaneously be- comes hyperpigmented within 1-3 weeks. However, these local reactions can be prevented by applying IV infusion for a short period (15-30 min) along with adequate venous irrigation (75-124 mL) instead of bolus administration. The termination of the drug can also be considered.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Sümbül, A. M. Sedef, C. Karaçin, C. Bilir, Baran Akagündüz
ABS TRACT Cancer is a disease in which some body cells with genetic or epigenetic changes become capable of replicating and invading other regions of the body uncontrollably. Numerous functional abilities and features are acquired by these cells during this multistage neoplastic process. In the last 20 years, many agents have been discovered and used in the fight against cancer. However, the use of these drugs in appropriate patient groups is still a serious problem. Many cancer types are on the way to becoming chronic diseases; conscientious physicians who are unable to provide appropriate treatment due to economic factors and other reasons face an additional burden.
{"title":"By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with It","authors":"A. Sümbül, A. M. Sedef, C. Karaçin, C. Bilir, Baran Akagündüz","doi":"10.37047/jos.2022-90068","DOIUrl":"https://doi.org/10.37047/jos.2022-90068","url":null,"abstract":"ABS TRACT Cancer is a disease in which some body cells with genetic or epigenetic changes become capable of replicating and invading other regions of the body uncontrollably. Numerous functional abilities and features are acquired by these cells during this multistage neoplastic process. In the last 20 years, many agents have been discovered and used in the fight against cancer. However, the use of these drugs in appropriate patient groups is still a serious problem. Many cancer types are on the way to becoming chronic diseases; conscientious physicians who are unable to provide appropriate treatment due to economic factors and other reasons face an additional burden.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: Telomerase reverse transcriptase (TERT) is one of the catalytic subunits of the telomerase enzyme involved in the lengthening of telomeres during cell division. Two hotspot mutations in the promoter region of the TERT gene, C228T and C250T have been observed in many different types of cancer. Besides, a limited number of available studies are related to colorectal cancer. However, no study to date has analyzed these mutations in the Turkish population. Hence, this study aimed to determine the frequency of C228T and C250T hotspot mutations in Turkish patients with colorectal cancer. Material and Methods: Tumors and adjacent healthy tissues of 43 colorectal cancer patients were analyzed in the study material. After genomic DNA extraction, 163 bp DNA fragment of the TERT promoter region was amplified by polymerase chain reaction (PCR) method. PCR products were sequenced using the bi-directional Sanger technique and a wild- type TERT promoter sequence obtained from the National Center for Biotechnology Information database was used for the comparison and detection of mutations. Results: Sequence analysis revealed no mutations in the promoter region of the TERT gene in colorectal cancer tis- sues or in healthy tissues. Conclusion: These findings of the study suggest that colorectal cancer in the Turkish population is not associated with the TERT promoter C228T and C250T hotspot mutations.
{"title":"Lack of Telomerase Reverse Transcriptase Promoter C228T and C250T Hotspot Mutations in Colorectal Cancer Patients in Türkiye","authors":"Türkan Gürer, Nisreen AL DOORI","doi":"10.37047/jos.2021-84899","DOIUrl":"https://doi.org/10.37047/jos.2021-84899","url":null,"abstract":"ABS TRACT Objective: Telomerase reverse transcriptase (TERT) is one of the catalytic subunits of the telomerase enzyme involved in the lengthening of telomeres during cell division. Two hotspot mutations in the promoter region of the TERT gene, C228T and C250T have been observed in many different types of cancer. Besides, a limited number of available studies are related to colorectal cancer. However, no study to date has analyzed these mutations in the Turkish population. Hence, this study aimed to determine the frequency of C228T and C250T hotspot mutations in Turkish patients with colorectal cancer. Material and Methods: Tumors and adjacent healthy tissues of 43 colorectal cancer patients were analyzed in the study material. After genomic DNA extraction, 163 bp DNA fragment of the TERT promoter region was amplified by polymerase chain reaction (PCR) method. PCR products were sequenced using the bi-directional Sanger technique and a wild- type TERT promoter sequence obtained from the National Center for Biotechnology Information database was used for the comparison and detection of mutations. Results: Sequence analysis revealed no mutations in the promoter region of the TERT gene in colorectal cancer tis- sues or in healthy tissues. Conclusion: These findings of the study suggest that colorectal cancer in the Turkish population is not associated with the TERT promoter C228T and C250T hotspot mutations.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gürbüz, I. Dogan, E. Akkuş, I. Karadag, S. Karakaya, C. Erol, R. Acar, Mert Karaoğlan, E. B. Köksoy, B. Savaş, M. Şendur, D. Taştekin, N. Karadurmuş, Ö. B. Çakmak Öksüzoğlu, F. Çay Şenler
ABS TRACT Objective: Data available on the rate of human epidermal growth factor receptor 2 (HER2) positivity and clinicopathological parameters related to it are heterogeneous. Hence, it is pertinent to investigate these parameters in different populations. This study aims to determine the frequency of HER2 positivity and clinicopathological factors associated with it in metastatic gastric cancer patients in a Turk- ish population. Material and Methods: This study included 552 patients with metastatic gastric cancer from 5 oncology centers. HER2 status, age, gender, smoking and alcohol history, body mass index, basal carcino embryonic antigen (CEA) level, basal cancer antigen 19-9 (CA 19-9) level, tumor localization, de-novo metastatic cancer, Lauren classification, signet-ring cell component, venous and neural invasion, and histological grade data were collected retrospectively. HER2 positivity was defined as an immunohistochemistry (IHC) score of 3+ or an IHC score of 2+ and in situ hybridization positive. Univariable and multivariable logistic regression analyses were used to detect clinicopathological factors associated with HER2 status. Results: A total of 100 patients (18.1%) were HER2-positive. Alcohol consumption, basal CEA level, basal CA 19-9 level, and signet-ring cell component were found to be statistically significant in univariable analysis. Alcohol use, basal CEA level, and having signet-ring cell component were statistically significant in the multivariable analysis. Odds ratios of alcohol use, high basal CEA and having signet-ring component were 2.35 (95% confidence interval (CI): 1.27-4.36, p=0.006), 1.99 (95% CI: 1.19-3.36, p=0.009), and 0.39 (95% CI: 0.22-0.71, p=0.002) respectively. Conclusion: HER2 positivity was detected in 18.1% of metastatic gastric cancer patients in the Turkish population. Alcohol use and basal CEA level were positively, and the signet-ring cell component was negatively correlated with HER2 positivity.
{"title":"Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study","authors":"M. Gürbüz, I. Dogan, E. Akkuş, I. Karadag, S. Karakaya, C. Erol, R. Acar, Mert Karaoğlan, E. B. Köksoy, B. Savaş, M. Şendur, D. Taştekin, N. Karadurmuş, Ö. B. Çakmak Öksüzoğlu, F. Çay Şenler","doi":"10.37047/jos.2021-86554","DOIUrl":"https://doi.org/10.37047/jos.2021-86554","url":null,"abstract":"ABS TRACT Objective: Data available on the rate of human epidermal growth factor receptor 2 (HER2) positivity and clinicopathological parameters related to it are heterogeneous. Hence, it is pertinent to investigate these parameters in different populations. This study aims to determine the frequency of HER2 positivity and clinicopathological factors associated with it in metastatic gastric cancer patients in a Turk- ish population. Material and Methods: This study included 552 patients with metastatic gastric cancer from 5 oncology centers. HER2 status, age, gender, smoking and alcohol history, body mass index, basal carcino embryonic antigen (CEA) level, basal cancer antigen 19-9 (CA 19-9) level, tumor localization, de-novo metastatic cancer, Lauren classification, signet-ring cell component, venous and neural invasion, and histological grade data were collected retrospectively. HER2 positivity was defined as an immunohistochemistry (IHC) score of 3+ or an IHC score of 2+ and in situ hybridization positive. Univariable and multivariable logistic regression analyses were used to detect clinicopathological factors associated with HER2 status. Results: A total of 100 patients (18.1%) were HER2-positive. Alcohol consumption, basal CEA level, basal CA 19-9 level, and signet-ring cell component were found to be statistically significant in univariable analysis. Alcohol use, basal CEA level, and having signet-ring cell component were statistically significant in the multivariable analysis. Odds ratios of alcohol use, high basal CEA and having signet-ring component were 2.35 (95% confidence interval (CI): 1.27-4.36, p=0.006), 1.99 (95% CI: 1.19-3.36, p=0.009), and 0.39 (95% CI: 0.22-0.71, p=0.002) respectively. Conclusion: HER2 positivity was detected in 18.1% of metastatic gastric cancer patients in the Turkish population. Alcohol use and basal CEA level were positively, and the signet-ring cell component was negatively correlated with HER2 positivity.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Ergün, G. Ucar, S. Aktürk Esen, M. Bardakçi, Z. Kalkan, Z. Urakçı, Erdoğan Şeyran, M. Doğan, G. Imamoglu, O. Yazıcı, S. Kahraman, Y. Açıkgöz, D. Uncu
ABS TRACT Objective: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and sur- vival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the patients was 57 (range: 24-83 years) years, and 67% (n=60) of the patients were male. Moreover, 43%, 18%, 9%, and 30% of the patients had blood groups A, B, AB, and O, respectively. Our study had a median follow-up time of 11 months. Although the groups did not differ significantly in progression-free survival (PFS) and overall survival (OS) according to the blood groups, patients who had the B blood type survived longer. For patients with blood types A, B, AB, and O, the median PFS was 5.3 months, 8.4 months, 3.7 months, and 7.8 months, respectively (p=0.8), and the median OS was 14.5 months, 20.3 months, 12.0 months, and 16.5 months, respectively (p=0.8). Conclusion: Although the groups did not differ significantly according to the ABO blood group, the patients with the B blood group survived relatively longer. These results sug-gested that further studies with more patients should be conducted.
{"title":"Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma","authors":"Y. Ergün, G. Ucar, S. Aktürk Esen, M. Bardakçi, Z. Kalkan, Z. Urakçı, Erdoğan Şeyran, M. Doğan, G. Imamoglu, O. Yazıcı, S. Kahraman, Y. Açıkgöz, D. Uncu","doi":"10.37047/jos.2022-90679","DOIUrl":"https://doi.org/10.37047/jos.2022-90679","url":null,"abstract":"ABS TRACT Objective: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and sur- vival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the patients was 57 (range: 24-83 years) years, and 67% (n=60) of the patients were male. Moreover, 43%, 18%, 9%, and 30% of the patients had blood groups A, B, AB, and O, respectively. Our study had a median follow-up time of 11 months. Although the groups did not differ significantly in progression-free survival (PFS) and overall survival (OS) according to the blood groups, patients who had the B blood type survived longer. For patients with blood types A, B, AB, and O, the median PFS was 5.3 months, 8.4 months, 3.7 months, and 7.8 months, respectively (p=0.8), and the median OS was 14.5 months, 20.3 months, 12.0 months, and 16.5 months, respectively (p=0.8). Conclusion: Although the groups did not differ significantly according to the ABO blood group, the patients with the B blood group survived relatively longer. These results sug-gested that further studies with more patients should be conducted.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: We determined the prognostic factors of patients with triple-negative breast cancer. Material and Method: Two hundred thirteen female patients with triple-negative breast cancer (TNBC) followed in the medical oncology unit of Kartal Doctor Lütfi K ı rdar City Hospital between 2005 and 2020 were evaluated retrospectively. Patients’ clinical and demographic features, laboratory findings, and treatments were investigated and their effect on mortality was analyzed. Results: The median age of patients was 52 years. Relapse was observed in 46 (26.6%) patients, 127 patients were followed without progression. During the follow-up period, 57 patients died and 156 pa- tients survived. The median overall survival was 137.2 months in patients with tumor size <2 cm, 109.9 months in patients with ≥ 2 cm and <5 cm, and 90.5 months in patients with ≥ 5 cm (p=0.02). Tumor diameter, lymph node positivity, menopausal status, and whether receiving neoadjuvant chemotherapy were determined as factors affecting the overall survival. Conclusion: In accordance with the literature, patients with TNBC showed more aggressive characteristics. Our findings support that TNBC is a heterogeneous disease and highlight the need to de- fine molecular subclasses. We believe that demographic and prognostic data studies with large patient series and determining molecular markers will guide the follow-up and treatment of patients with TNBC.
{"title":"Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience","authors":"A. Dogan, M. Ayhan","doi":"10.37047/jos.2022-89749","DOIUrl":"https://doi.org/10.37047/jos.2022-89749","url":null,"abstract":"ABS TRACT Objective: We determined the prognostic factors of patients with triple-negative breast cancer. Material and Method: Two hundred thirteen female patients with triple-negative breast cancer (TNBC) followed in the medical oncology unit of Kartal Doctor Lütfi K ı rdar City Hospital between 2005 and 2020 were evaluated retrospectively. Patients’ clinical and demographic features, laboratory findings, and treatments were investigated and their effect on mortality was analyzed. Results: The median age of patients was 52 years. Relapse was observed in 46 (26.6%) patients, 127 patients were followed without progression. During the follow-up period, 57 patients died and 156 pa- tients survived. The median overall survival was 137.2 months in patients with tumor size <2 cm, 109.9 months in patients with ≥ 2 cm and <5 cm, and 90.5 months in patients with ≥ 5 cm (p=0.02). Tumor diameter, lymph node positivity, menopausal status, and whether receiving neoadjuvant chemotherapy were determined as factors affecting the overall survival. Conclusion: In accordance with the literature, patients with TNBC showed more aggressive characteristics. Our findings support that TNBC is a heterogeneous disease and highlight the need to de- fine molecular subclasses. We believe that demographic and prognostic data studies with large patient series and determining molecular markers will guide the follow-up and treatment of patients with TNBC.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：